Related Experiment Video
Updated: Jul 8, 2026
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Plasma Small Extracellular Vesicle microRNAs as Non-Invasive Biomarkers for Lung Cancer Detection
Qiaoli Lv1, Yangzhong Guo1, Xiaoya Xu2
1Thoracic Oncology Laboratory, Jiangxi Key Laboratory of Oncology, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330029, People's Republic of China.
This study identifies specific microRNAs (miRNAs) in plasma small extracellular vesicles (sEVs) as accurate biomarkers for early lung cancer (LC) detection. These novel non-invasive biomarkers show high sensitivity and specificity, offering a promising tool for early diagnosis.
Area of Science:
- Biomarkers and Diagnostics
- Molecular Biology
- Oncology
Background:
- Current non-invasive lung cancer (LC) detection methods lack sufficient diagnostic accuracy and clinical validation.
- There is a critical need for validated, sensitive, and specific non-invasive biomarkers for early LC detection.
Purpose of the Study:
- To identify and validate microRNA (miRNA) expression signatures in plasma-derived small extracellular vesicles (sEVs) as non-invasive biomarkers for early-stage lung cancer (LC).
- To develop and assess a diagnostic model based on sEV miRNA profiles for discriminating between LC patients and non-malignant controls.
Main Methods:
- Small RNA sequencing was used to analyze miRNA expression in plasma sEVs from individuals with LC (Stages I/II) and non-malignant controls (NCs).
- A diagnostic model was developed using a training cohort (n=80) and validated in an independent cohort (n=52).
- Model performance was evaluated using metrics including Area Under the Curve (AUC), sensitivity, and specificity.
Main Results:
- A signature of 14 differentially expressed sEV miRNAs was identified between NCs and LC samples.
- A diagnostic model incorporating eight specific miRNAs (hsa-miR-423-5p, hsa-miR-340-3p, hsa-miR-320b, hsa-miR-98-5p, hsa-miR-26a-5p, hsa-miR-193b-5p, hsa-miR-629-5p, and hsa-miR-92b-5p) demonstrated high performance.
- The model achieved an AUC of 0.956 (sensitivity 94%, specificity 93%) in the training cohort and an AUC of 0.985 (sensitivity 86%, specificity 97%) in the validation cohort.
Conclusions:
- Plasma sEV miRNAs serve as highly discriminative biomarkers for differentiating early-stage lung cancer from non-malignant conditions.
- These findings highlight the potential of plasma sEV miRNA profiles as a promising auxiliary tool for the early detection of lung cancer.
